ReviewDigestive diseases and sciences2016
Histological Assessment of NAFLD.
Review in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Acute Effects of Cannabinoid Combination Therapies in a Western Diet-Induced Murine Model of Metabolic Liver Disease.International journal of molecular sciences · 2026Article
- Zonation, Zonation, Zonation: The Real Estate of the Liver.Annual review of pathology · 2026Review
- Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments.World journal of gastroenterology · 2023Review
- Hepatic transcriptome signatures in mice and humans with nonalcoholic fatty liver disease.Animal models and experimental medicine · 2023Article
- Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration.Nutrients · 2022Review
- Associations between subcutaneous adipocyte hypertrophy and nonalcoholic fatty liver disease.Scientific reports · 2022Article
- Article
- Combining a β3 adrenergic receptor agonist with alpha-lipoic acid reduces inflammation in male mice with diet-induced obesity.Obesity (Silver Spring, Md.) · 2022Article
- Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets?Biomedicines · 2021Review
- Extracellular Vesicles as Drivers of Non-Alcoholic Fatty Liver Disease: Small Particles with Big Impact.Biomedicines · 2021Review
- Metabolic alterations and vulnerabilities in hepatocellular carcinoma.Gastroenterology report · 2021Review
- Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?Advances in nutrition (Bethesda, Md.) · 2020Review
- The metabolic basis of nonalcoholic steatohepatitis.Endocrinology, diabetes & metabolism · 2020Review
- Exploring the genetic basis of fatty liver development in geese.Scientific reports · 2020Article
- Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Inter-observer Variability in Histomorphological Evaluation of Non-neoplastic Liver Biopsy Tissue and Impact of Clinical Information on Final Diagnosis in Shahid Beheshti University of Medical Sciences Affiliated Hospitals.Iranian journal of pathology · 2019Article
- A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity.Internal medicine (Tokyo, Japan) · 2018Article
- Article
- Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis.Hepatology international · 2018Review
- Non-alcoholic fatty liver disease: An expanded review.World journal of hepatology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of histological lesions ranging from steatosis to a complex pattern with hepatocyte injury and inflammation in an appropriate clinical context. The disease has been artificially dichotomized into NAFL (steatosis) and NASH (steatosis with hepatocellular injury and inflammation), but it is increasingly clear that intermediate patterns may exist. More than NASH, the stage of fibrosis was shown to govern prognosis, and for such evaluation, a liver biopsy of adequate size and width is needed. Like for any other chronic liver diseases, semi-quantitative histologic scores have been proposed. They are not useful in clinical practice but concur to categorize homogeneous group of patients according to their histology. Pediatric NAFLD is a growing concern. While a subgroup of children may harbor different but characteristic histological patterns, most of them display a mixed pattern or features similar to the adults. Today, liver histology is the mainstay for clinical trials. Biopsy is used both for enrollment and for assessing benefit of clinical trials. End points such as reversion of NASH or regression of fibrosis are acceptable but require a clear histological definition.
Indexed as
Identifiers
26874689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.